ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0757

Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study

Paul Studenic1, Aliaksandra Baranskaya2, Stanley Cohen3, Nancy Shadick4, Christine Iannaccone5, Maria Dahl Mjaavatten6, Elisabeth Lie7, Tore Kvien8, Josef Smolen9, Daniel Aletaha10 and Helga Radner9, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Metroplex Clinical Research Center, Dallas, TX, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women’s Hospital, Topsfield, MA, 6Diakonhjemmet Hospital, Haslum, Norway, 7Diakonhjemmet Hospital, Oslo, Nepal, 8Diakonhjemmet Hospital, Oslo, Norway, 9Medical University of Vienna, Vienna, Austria, 10Medical University Vienna, Vienna, Austria

Meeting: ACR Convergence 2021

Keywords: Disease Activity, Measurement Instrument, Outcome measures, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The patient global assessment (PGA), typically assessed as ‘Considering all of the ways your arthritis has affected you, how do you feel your arthritis is today?‘ should reflect the patient’s perception of disease activity. It is incorporated as core set measure of disease activity in rheumatoid arthritis (RA) but has been criticized to not adequately fulfill its construct validity.

We explore different versions of the PGA and assess agreement, factors of variance, change over time and effect on disease activity classification.

Methods: In a multicenter study (4 centers in US & Europe), RA patients were asked to score on global health (GH) and 6 differently phrased PGA questions using visual analogue scale covering 2 aspects: (1) providing more detailed explanation on disease activity (“Active arthritis can cause joint swelling OR stiffness, pain OR discomfort in your joints. WITH ACTIVE ARTHRITIS, You CAN BE tired during the day, even when you’ve slept well“ (ePGA) compared to traditional phrasing (tPGA); and (2) reference to 3 time periods: today (TD), last week (LW) or last month (LM). This generated 3 tPGA versions (TD/LW/LM) and 3 ePGA versions (TD/LW/LM). Agreement was calculated with intra-class correlation (ICC) and comparisons between PGA were done with paired-analyses. The empirical variation coefficient (eVC: (SD/mean)/SQRT(n)) was calculated per patient. The influence of disease duration, HAQ >0.5 or ≤0.5, SJC28, TJC28, fatigue and evaluator global assessment (EGA) on scoring of PGA versions were assessed and the resulting variations in disease activity classification.

Results: At baseline (BL) 189 patients (82% female, 45%≥1 comorbidity, mean disease duration ±SD: 16.6±10.8, mean PGA: 31.8±22.7, mean eVC 0.15±0.15, mean SJC28: 1.6±2.3) and 138 with follow-up (FU) were subjected to analyses. In paired analyses ePGA were scored higher than tPGA (p≤0.001) and in both, scores were higher in longer reference periods. When comparing in between reference periods (Table 1), ICCs were all ranging >0.8. Changes in PGA between BL and FU reached high agreement, except for TD versus LM. Poor to moderate agreement both for BL, as well as change scores, were found between versions of PGA and GH (Table 1). BL to FU PGA changes correlated highly with changes in pain and moderately with changes in EGA. The difference between PGA and GH (LW, LM versions) increases with more swollen joints. Differences between phrasings were less pronounced in patients with HAQ >0.5 or with comorbidities. The variance in scores between questions was lower in people with higher disease activity. Higher mean PGA, fatigue, TJC, SJC and EGA correlated moderately with smaller eVC (Figure 1). The rate of patients switching CDAI disease activity level is around 8% when comparing tPGA with ePGA, but between 15% to 20% in PGA/GH and around 14% in TD/LM (Figure 2). Only up to 3% less achieve REM/LDA CDAI when switching to ePGA, however GH use instead of PGA coincides with 5 to 7% of patients less in Boolean remission.

Conclusion: Different versions of the PGA show high correlation, implicating that a more detailed phrasing would not increase construct validity. GH performs differently than PGA and may not be used interchangeably.


Disclosures: P. Studenic, None; A. Baranskaya, None; S. Cohen, Amgen, 5, Abbvie, 2, 5, Boehringer Ingelheim, 2, 5, Gilead, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 2, 5; N. Shadick, Amgen, 5, BMS, 2, 5, Eli Lilly, 5, Sanofi, 5, Mallinckrodt, 5; C. Iannaccone, None; M. Mjaavatten, None; E. Lie, None; T. Kvien, Biogen, 6, Celltrion, 6, Egis, 6, Eli Lilly, 6, Evapharma, 6, Ewopharma, 6, Gilead, 6, Hikma, 6, Mylan, 6, Oktal, 6, Sandoz, 6, Sanofi, 6, Abbvie, 5, 6, BMS, 5, MSD, 5, Novartis, 5, 6, Pfizer, 5, 6, Amgen, 5, 6, UCB, 5; J. Smolen, AbbVie, 2, 5, BMS, 2, 5, Celegene, 2, 5, Chugai, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Eli Lilly, 2, 5, MSD, 2, 5, Novartis-Sandoz, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Samsung, 2, 5, Sanofi, 2, 5, UCB, 2, 5; D. Aletaha, AbbVie, 2, 5, Janssen, 2, 5, Medac, 2, 5, Merck, 2, 5, 6, Pfizer, 2, 5, Roche, 2, 5, UCB, 2, 5, Novartis, 2, 5, 6, Bristol-Myers Squibb, 6, Amgen, 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6; H. Radner, None.

To cite this abstract in AMA style:

Studenic P, Baranskaya A, Cohen S, Shadick N, Iannaccone C, Mjaavatten M, Lie E, Kvien T, Smolen J, Aletaha D, Radner H. Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/different-versions-of-the-patient-global-question-in-rheumatoid-arthritis-does-it-really-matter-results-of-a-multi-center-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-versions-of-the-patient-global-question-in-rheumatoid-arthritis-does-it-really-matter-results-of-a-multi-center-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology